Differences in PARP Inhibitors for the Treatment of Ovarian Cancer: Mechanisms of Action, Pharmacology, Safety, and Efficacy

PARP inhibitors: Synthetic lethality in the clinic

Lord, C. J., & Ashworth, A. (2017) · Science · doi:10.1126/science.aam7344 · Cited by 2,932 · see citing works

Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer

Moore, K., Colombo, N., Scambia, G., Kim, B.-G., Oaknin, A., Friedlander, M., Lisyanskaya, A., Floquet, A., Leary, A., Sonke, G. S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1810858 · Cited by 2,870 · see citing works

Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer

Mirza, M. R., Monk, B. J., Herrstedt, J., Oza, A. M., Mahner, S., Redondo, A., Fabbro, M., Ledermann, J. A., Lorusso, D., Vergote, I. B., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1611310 · Cited by 2,452 · see citing works

Comprehensive analysis of kinase inhibitor selectivity

Davis, M. I., Hunt, J. P., Herrgard, S., Ciceri, P., Wodicka, L. M., Pallares, G., Hocker, M., Treiber, D. K., & Zarrinkar, P. P. (2011) · Nature Biotechnology · doi:10.1038/nbt.1990 · Cited by 2,409 · see citing works

Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer

González-Martı́n, A., Pothuri, B., Vergote, I. B., Christensen, R. D., Graybill, W. A. S., Mirza, M. R., McCormick, C., Lorusso, D., Hoskins, P. J., Freyer, G., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1910962 · Cited by 2,278 · see citing works

Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors

Murai, J., Huang, S.-Y. N., Das, B. B., Renaud, A., Zhang, Y., Doroshow, J. H., Ji, J. J., Takeda, S., & Pommier, Y. G. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-2753 · Cited by 2,217 · see citing works

Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer

Ray-Coquard, I. L., Pautier, P., Pignata, S., Pérol, D., González-Martı́n, A., Berger, R., Fujiwara, K., Vergote, I. B., Colombo, N., Maenpaa, J. U., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911361 · Cited by 2,072 · see citing works

Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer

Ledermann, J. A., Harter, P., Gourley, C., Friedlander, M. L., Vergote, I. B., Rustin, G. J. S., Scott, C. L., Meier, W., Shapira‐Frommer, R., Safra, T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1105535 · Cited by 1,891 · see citing works

Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial

Pujade-Lauraine, É., Ledermann, J. A., Selle, F., Gebski, V., Penson, R. T., Oza, A. M., Korach, J., Huzarski, T., Poveda, A. M., Pignata, S., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30469-2 · Cited by 1,856 · see citing works

Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation

Kaufman, B., Shapira‐Frommer, R., Schmutzler, R. K., Audeh, M. W., Friedlander, M. L., Balmañà, J., Mitchell, G., Fried, G., Stemmer, S. M., Hubert, A., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.2728 · Cited by 1,707 · see citing works

Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial

Coleman, R. L., Oza, A. M., Lorusso, D., Aghajanian, C. A., Oaknin, A., Dean, A. P., Colombo, N., Weberpals, J. I., Clamp, A. R., Scambia, G., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32440-6 · Cited by 1,699 · see citing works

PARP inhibition: PARP1 and beyond

Rouleau, M., Patel, A., Hendzel, M. J., Kaufmann, S. H., & Poirier, G. G. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2812 · Cited by 1,298 · see citing works

Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer

Coleman, R. L., Fleming, G. F., Brady, M. F., Swisher, E. M., Steffensen, K. D., Friedlander, M. L., Okamoto, A., Moore, K. N., Ben-Baruch, N. E., Werner, T. L., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1909707 · Cited by 915 · see citing works

Integrating Genetic Approaches into the Discovery of Anticancer Drugs

Hartwell, L. H., Szankasi, P., Roberts, C. J., Murray, A. W., & Friend, S. H. (1997) · Science · doi:10.1126/science.278.5340.1064 · Cited by 777 · see citing works

Review of Poly (ADP-ribose) Polymerase (PARP) Mechanisms of Action and Rationale for Targeting in Cancer and Other Diseases

Morales, J. C., Li, L.-S., Fattah, F. J., Dong, Y., Bey, E. A., Patel, M., Gao, J., & Boothman, D. A. (2013) · Critical Reviews in Eukaryotic Gene Expression · doi:10.1615/critreveukaryotgeneexpr.2013006875 · Cited by 613 · see citing works

PARP1-dependent Kinetics of Recruitment of MRE11 and NBS1 Proteins to Multiple DNA Damage Sites

Haince, J.-F., McDonald, D., Rodrigue, A., Déry, U., Masson, J., Hendzel, M. J., & Poirier, G. G. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m706734200 · Cited by 609 · see citing works

Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial

Moore, K. N., Secord, A. A., Geller, M. A., Miller, D. S., Cloven, N. G., Fleming, G. F., Hendrickson, A. E. W., Azodi, M., DiSilvestro, P., Oza, A. M., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30029-4 · Cited by 532 · see citing works

Sex and Gender Differences in the Outcomes of Vaccination over the Life Course

Flanagan, K. L., Fink, A. L., Plebanski, M., & Klein, S. L. (2017) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev-cellbio-100616-060718 · Cited by 508 · see citing works

ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer

Miller, R. E., Leary, A. F., Scott, C. L., Serra, V., Lord, C. J., Bowtell, D. D. L., Chang, D. K.-F., Garsed, D. W., Jonkers, J., Ledermann, J. A., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.08.2102 · Cited by 483 · see citing works

Family-wide chemical profiling and structural analysis of PARP and tankyrase inhibitors

Wahlberg, E., Karlberg, T., Kouznetsova, E., Markova, N., Macchiarulo, A., Thorsell, A. G., Pol, E., Frostell, Å., Ekblad, T., Öncü, D., et al. (2012) · Nature Biotechnology · doi:10.1038/nbt.2121 · Cited by 460 · see citing works

Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial

Poveda, A. M., Floquet, A., Ledermann, J. A., Asher, R., Penson, R. T., Oza, A. M., Korach, J., Huzarski, T., Pignata, S., Friedlander, M. L., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00073-5 · Cited by 426 · see citing works

DNA Damage/Repair Management in Cancers

Alhmoud, J. F., Woolley, J. F., Moustafa, A. A., & Malki, M. I. (2020) · Cancers · doi:10.3390/cancers12041050 · Cited by 378 · see citing works

The forefront of ovarian cancer therapy: update on PARP inhibitors

Mirza, M. R., Coleman, R. L., González-Martı́n, A., Moore, K. N., Colombo, N., Ray-Coquard, I., & Pignata, S. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.06.004 · Cited by 371 · see citing works

Structural Basis for Potency and Promiscuity in Poly(ADP-ribose) Polymerase (PARP) and Tankyrase Inhibitors

Thorsell, A. G., Ekblad, T., Karlberg, T., Löw, M., Pinto, A. F., Tresaugues, L., Moche, M., Cohen, M. S., & Schuler, H. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00990 · Cited by 369 · see citing works

Myelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: a safety meta-analysis of randomised controlled trials and a retrospective study of the WHO pharmacovigilance database

Morice, P., Leary, A. F., Dolladille, C., Chrétien, B., Poulain, L., González-Martı́n, A., Moore, K. N., O'Reilly, E. M., Ray-Coquard, I. L., & Alexandre, J. (2020) · The Lancet Haematology · doi:10.1016/s2352-3026(20)30360-4 · Cited by 256 · see citing works

A Phase I–II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline BRCA1/2 -Mutated Ovarian Carcinoma or Other Solid Tumors

Kristeleit, R. S., Shapiro, G. I., Burris, H. A., Oza, A. M., LoRusso, P. M., Patel, M. R., Domchek, S. M., Balmañà, J., Drew, Y., Chen, L.-M., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2796 · Cited by 244 · see citing works

PARP1 and PARP2 stabilise replication forks at base excision repair intermediates through Fbh1-dependent Rad51 regulation

Ronson, G. E., Piberger, A. L., Higgs, M. R., Olsen, A. L., Stewart, G. D., McHugh, P. J., Petermann, E., & Lakin, N. D. (2018) · Nature Communications · doi:10.1038/s41467-018-03159-2 · Cited by 227 · see citing works

Multifaceted Role of PARP-1 in DNA Repair and Inflammation: Pathological and Therapeutic Implications in Cancer and Non-Cancer Diseases

Pazzaglia, S., & Pioli, C. (2019) · Cells · doi:10.3390/cells9010041 · Cited by 223 · see citing works

Niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer using an individualized starting dose (NORA): a randomized, double-blind, placebo-controlled phase III trial☆

Wu, X., Zhu, J., Yin, R., Yang, J., Liu, J., Wang, J., Wu, L., Liu, Z. L., Gao, Y., Wang, D. B., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2020.12.018 · Cited by 201 · see citing works

Safety and dose modification for patients receiving niraparib

Berek, J. S., Matulonis, U. A., Peen, U., Ghatage, P., Mahner, S., Redondo, A., Lesoin, A., Colombo, N., Vergote, I. B., Rosengarten, O. S., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy181 · Cited by 188 · see citing works

FDA Approval Summary: Olaparib Monotherapy or in Combination with Bevacizumab for the Maintenance Treatment of Patients with Advanced Ovarian Cancer

Arora, S., Balasubramaniam, S., Zhang, H., Berman, T. A., Narayan, P., Suzman, D. L., Bloomquist, E. W., Tang, S. W., Gong, Y. U. T., Sridhara, R., et al. (2020) · The Oncologist · doi:10.1002/onco.13551 · Cited by 183 · see citing works

PARP-2 sustains erythropoiesis in mice by limiting replicative stress in erythroid progenitors

Farrés, J., Llacuna, L., Martín‐Caballero, J., Martínez, C. M., Lozano, J. J., Ampurdanés, C., Lopez-Contreras, A. J., Florensa, L., Navarro, J., Ottina, E., et al. (2014) · Cell Death and Differentiation · doi:10.1038/cdd.2014.202 · Cited by 179 · see citing works

PARP1-Driven Poly-ADP-Ribosylation Regulates BRCA1 Function in Homologous Recombination–Mediated DNA Repair

Hu, Y., Petit, S. A., Ficarro, S. B., Toomire, K. J., Xie, A., Lim, E., Cao, S. A., Park, E., Eck, M. J., Scully, R., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0891 · Cited by 171 · see citing works

TNF-induced necroptosis and PARP-1-mediated necrosis represent distinct routes to programmed necrotic cell death

Sosna, J., Voigt, S., Mathieu, S., Lange, A., Thon, L., Davarnia, P., Herdegen, T., Linkermann, A., Rittger, A., Chan, F. K.-M., et al. (2013) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-013-1381-6 · Cited by 162 · see citing works

PARP Inhibitors in Ovarian Cancer

Mittica, G., Ghisoni, E., Giannone, G., Genta, S., Aglietta, M., Sapino, A., & Valabrega, G. (2018) · Recent Patents on Anti-Cancer Drug Discovery · doi:10.2174/1574892813666180305165256 · Cited by 158 · see citing works

Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial

Ledermann, J. A., Oza, A. M., Lorusso, D., Aghajanian, C. A., Oaknin, A., Dean, A. P., Colombo, N., Weberpals, J. I., Clamp, A. R., Scambia, G., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30061-9 · Cited by 131 · see citing works

The PARP family: insights into functional aspects of poly ( ADP ‐ribose) polymerase‐1 in cell growth and survival

Jubin, T., Kadam, A. A., Jariwala, M., Bhatt, S., Sutariya, S., Gani, A. R., Gautam, S., & Begum, R. (2016) · Cell Proliferation · doi:10.1111/cpr.12268 · Cited by 130 · see citing works

The kinase polypharmacology landscape of clinical PARP inhibitors

Antolín, A. A., Ameratunga, M., Banerji, U., Clarke, P. A., Workman, P., & Al‐Lazikani, B. (2020) · Scientific Reports · doi:10.1038/s41598-020-59074-4 · Cited by 126 · see citing works

Therapeutic Potential of the Poly(ADP-ribose) Polymerase Inhibitor Rucaparib for the Treatment of Sporadic Human Ovarian Cancer

Ihnen, M., zu Eulenburg, C., Kolarova, T. R., Qi, J. W., Manivong, K., Chalukya, M., Dering, J., Anderson, L. A., Ginther, C., Meuter, A., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0813 · Cited by 111 · see citing works

Clinical assays for assessment of homologous recombination DNA repair deficiency

Stover, E. H., Fuh, K. C., Konstantinopoulos, P. A., Matulonis, U. A., & Liu, J. F. (2020) · Gynecologic Oncology · doi:10.1016/j.ygyno.2020.09.029 · Cited by 109 · see citing works

Final overall survival (OS) results from SOLO2/ENGOT-ov21: A phase III trial assessing maintenance olaparib in patients (pts) with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation.

Poveda, A. M., Floquet, A., Ledermann, J. A., Asher, R., Penson, R. T., Oza, A. M., Korach, J., Huzarski, T., Pignata, S., Friedlander, M. L., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.15_suppl.6002 · Cited by 107 · see citing works

Olaparib as maintenance therapy in patients with BRCA 1–2 mutated recurrent platinum sensitive ovarian cancer: Real world data and post progression outcome

Cecere, S. C., Giannone, G., Salutari, V., Arenare, L., Lorusso, D., Ronzino, G., Lauria, R., Cormio, G., Carella, C., Scollo, P., et al. (2019) · Gynecologic Oncology · doi:10.1016/j.ygyno.2019.10.023 · Cited by 106 · see citing works

Proteome-wide Profiling of Clinical PARP Inhibitors Reveals Compound-Specific Secondary Targets

Knezevic, C. E., Wright, G. M., Rix, L. L. R., Kim, W., Kuenzi, B. M., Luo, Y., Watters, J. M., Koomen, J. M., Haura, E. B., Monteiro, Á. N. A., et al. (2016) · Cell chemical biology · doi:10.1016/j.chembiol.2016.10.011 · Cited by 97 · see citing works

Rad17 recruits the MRE11‐RAD50‐NBS1 complex to regulate the cellular response to DNA double‐strand breaks

Wang, Q., Goldstein, M., Alexander, P. B., Wakeman, T. P., Sun, T., Feng, J., Lou, Z., Kastan, M. B., & Wang, X.-F. (2014) · The EMBO Journal · doi:10.1002/embj.201386064 · Cited by 92 · see citing works

Differential anti-proliferative activities of poly(ADP-ribose) polymerase (PARP) inhibitors in triple-negative breast cancer cells

Chuang, H.-C., Kapuriya, N. P., Kulp, S. K., Chen, C., & Shapiro, C. L. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2106-5 · Cited by 90 · see citing works

Effect of MRE11 Loss on PARP-Inhibitor Sensitivity in Endometrial Cancer In Vitro

Koppensteiner, R., Samartzis, E. P., Noske, A., von Teichman, A., Dedes, I., Gwerder, M., Imesch, P., Ikenberg, K., Moch, H., Fink, D. A., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0100041 · Cited by 90 · see citing works

A Phase I, dose‐finding and pharmacokinetic study of olaparib (AZD2281) in Japanese patients with advanced solid tumors*,†

Yamamoto, N., Nokihara, H., Yamada, Y., Goto, Y., Tanioka, M., Shibata, T., Yamada, K., Asahina, H., Kawata, T., Shi, X., et al. (2011) · Cancer Science · doi:10.1111/j.1349-7006.2011.02179.x · Cited by 73 · see citing works

Olaparib Tablets as Maintenance Therapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and a BRCA1/2 Mutation (SOLO2/ENGOT-Ov21): A Final Analysis of a Double-Blind, Randomised, Placebo-Controlled, Phase 3 Trial

Poveda, A. M., Floquet, A., Ledermann, J. A., Asher, R., Penson, R. T., Oza, A. M., Korach, J., Huzarski, T., Pignata, S., Friedlander, M. L., et al. (2021) · Obstetrical & Gynecological Survey · doi:10.1097/ogx.0000000000000962 · Cited by 69 · see citing works

811MO Maintenance olaparib for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): 5-year (y) follow-up (f/u) from SOLO1

Banerjee, S. N., Moore, K. N., Colombo, N., Scambia, G., Kim, B.-G., Oaknin, A., Friedlander, M. L., Lisyanskaya, A. S., Floquet, A., Leary, A. F., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.08.950 · Cited by 65 · see citing works

The poly (ADP ribose) polymerase inhibitor niraparib: Management of toxicities

Moore, K. N., Mirza, M. R., & Matulonis, U. A. (2018) · Gynecologic Oncology · doi:10.1016/j.ygyno.2018.01.011 · Cited by 64 · see citing works

Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancer

Ledermann, J. A., Harter, P., Gourley, C., Friedlander, M. L., Vergote, I. B., Rustin, G. J. S., Scott, C. L., Meier, W., Shapira‐Frommer, R., Safra, T., et al. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.348 · Cited by 58 · see citing works

The current landscape of molecular profiling in the treatment of epithelial ovarian cancer

Haunschild, C., & Tewari, K. S. (2020) · Gynecologic Oncology · doi:10.1016/j.ygyno.2020.09.043 · Cited by 57 · see citing works

Incorporating Parp-inhibitors in Primary and Recurrent Ovarian Cancer: A Meta-analysis of 12 phase II/III randomized controlled trials

Ruscito, I., Bellati, F., Ray-Coquard, I. L., Mirza, M. R., du Bois, A., Gasparri, M. L., Costanzi, F., Marco, M. P. D., Nuti, M., Caserta, D., et al. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102040 · Cited by 55 · see citing works

Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: Results from the phase III ENGOT-OV16/NOVA trial

Mirza, M. R., Benigno, B. B., Dørum, A., Mahner, S., Bessette, P., Bover, I., Berton-Rigaud, D., Ledermann, J. A., Rimel, B. J., Herrstedt, J., et al. (2020) · Gynecologic Oncology · doi:10.1016/j.ygyno.2020.09.006 · Cited by 55 · see citing works

PARP-mediated repair, homologous recombination, and back-up non-homologous end joining-like repair of single-strand nicks

Metzger, M. J., Stoddard, B. L., & Monnat, R. J. (2013) · DNA repair · doi:10.1016/j.dnarep.2013.04.004 · Cited by 51 · see citing works

Mammalian Base Excision Repair: Functional Partnership between PARP-1 and APE1 in AP-Site Repair

Prasad, R., Dyrkheeva, N. S., Williams, J. G., & Wilson, S. H. (2015) · PLoS ONE · doi:10.1371/journal.pone.0124269 · Cited by 49 · see citing works

Differential effects of poly(ADP-ribose) polymerase inhibition on DNA break repair in human cells are revealed with Epstein–Barr virus

Ma, W., Halweg, C., Menéndez, D., & Resnick, M. A. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1118078109 · Cited by 46 · see citing works

Patient-Centered Outcomes in ARIEL3, a Phase III, Randomized, Placebo-Controlled Trial of Rucaparib Maintenance Treatment in Patients With Recurrent Ovarian Carcinoma

Oza, A. M., Lorusso, D., Aghajanian, C. A., Oaknin, A., Dean, A. P., Colombo, N., Weberpals, J. I., Clamp, A. R., Scambia, G., Leary, A. F., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.03107 · Cited by 45 · see citing works

Pharmacokinetic Study of Rucaparib in Patients With Advanced Solid Tumors

Shapiro, G. I., Kristeleit, R. S., Burris, H. A., LoRusso, P. M., Patel, M. R., Drew, Y., Giordano, H., Maloney, L., Watkins, S. P., Goble, S. M., et al. (2018) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.575 · Cited by 43 · see citing works

Human mass balance study and metabolite profiling of 14C-niraparib, a novel poly(ADP-Ribose) polymerase (PARP)-1 and PARP-2 inhibitor, in patients with advanced cancer

van Andel, L., Zhang, Z., Lu, S. M., Kansra, V. V., Agarwal, S., Hughes, L., Tibben, M. M., Gebretensae, A., Lucas, L., Hillebrand, M. J. X., et al. (2017) · Investigational New Drugs · doi:10.1007/s10637-017-0451-2 · Cited by 40 · see citing works

Olaparib maintenance therapy in patients with newly diagnosed advanced ovarian cancer and a BRCA1 and/or BRCA2 mutation: SOLO1 China cohort

Wu, L., Zhu, J., Yin, R., Wu, X., Lou, G., Wang, J., Gao, Y., Kong, B., Lu, X., Zhou, Q., et al. (2020) · Gynecologic Oncology · doi:10.1016/j.ygyno.2020.10.005 · Cited by 40 · see citing works

Determination of the absolute oral bioavailability of niraparib by simultaneous administration of a 14C-microtracer and therapeutic dose in cancer patients

van Andel, L., Rosing, H., Zhang, Z., Hughes, L., Kansra, V. V., Sanghvi, M., Tibben, M. M., Gebretensae, A., Schellens, J. H. M., & Beijnen, J. H. (2017) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-017-3455-x · Cited by 39 · see citing works

Niraparib Maintenance Treatment Improves Time Without Symptoms or Toxicity (TWiST) Versus Routine Surveillance in Recurrent Ovarian Cancer: A TWiST Analysis of the ENGOT-OV16/NOVA Trial

Matulonis, U. A., Walder, L., Nøttrup, T. J., Bessette, P., Mahner, S., Gil-Martín, M., Kalbacher, E., Ledermann, J. A., Wenham, R. M., Woie, K., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00917 · Cited by 35 · see citing works

A Survey of Reported Disease-Related Mutations in the MRE11-RAD50-NBS1 Complex

Rahman, S., Canny, M. D., Buschmann, T. A., & Latham, M. P. (2020) · Cells · doi:10.3390/cells9071678 · Cited by 35 · see citing works

Evaluation of absorption, distribution, metabolism, and excretion of [14C]-rucaparib, a poly(ADP-ribose) polymerase inhibitor, in patients with advanced solid tumors

Liao, M., Watkins, S. P., Nash, E., Isaacson, J. D., Etter, J., Beltman, J., Fan, R., Shen, L., Mutlib, A. E., Kemény, V., et al. (2019) · Investigational New Drugs · doi:10.1007/s10637-019-00815-2 · Cited by 34 · see citing works

PARP-1 and YY1 Are Important Novel Regulators of CXCL12 Gene Transcription in Rat Pancreatic Beta Cells

Marković, J., Grdović, N., Dinić, S., Karan-Djurašević, T., Uskoković, A. S., Јovanović, J. A., Mihailović, M., Pavlović, S., Poznanović, G., & Vidaković, M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0059679 · Cited by 29 · see citing works

Frontline PARP inhibitor maintenance therapy in ovarian cancer: A Society of Gynecologic Oncology practice statement

Pothuri, B., O'Cearbhaill, R. E., Eskander, R. N., & Armstrong, D. K. (2020) · Gynecologic Oncology · doi:10.1016/j.ygyno.2020.07.097 · Cited by 26 · see citing works

The impact of poly ADP ribose polymerase (PARP) inhibitors on clonal hematopoiesis.

Bolton, K. L., Moukarzel, L. A., Ptashkin, R. N., Gao, T., Patel, M. A., Caltabellotta, N. M., Braunstein, L. Z., Aghajanian, C. A., Hyman, D. M., Berger, M. F., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.15_suppl.1513 · Cited by 24 · see citing works

Real-World Adverse Events with Niraparib 200 mg/Day Maintenance Therapy in Ovarian Cancer: A Retrospective Study

Gallagher, J. R., Heap, K., Carroll, S. L., Travers, K. U., Harrow, B. S., & Westin, S. N. (2019) · Future Oncology · doi:10.2217/fon-2019-0471 · Cited by 23 · see citing works

PARP-1 may be involved in hydroquinone-induced apoptosis by poly ADP-ribosylation of ZO-2

Liu, J., Yuan, Q., Ling, X., Tan, Q., Liang, H., Chen, J., Lin, L., Xiao, Y., Chen, W. L., Liu, L., et al. (2017) · Molecular Medicine Reports · doi:10.3892/mmr.2017.7643 · Cited by 18 · see citing works

Health-related quality of life (HRQOL) and patient-centered outcomes with maintenance olaparib compared with placebo following chemotherapy in patients with germline (g) BRCA-mutated (m) platinum-sensitive relapsed serous ovarian cancer (PSR SOC): SOLO2 phase III trial.

Friedlander, M. L., Gebski, V., Gibbs, E., Bloomfield, R., Hilpert, F., Wenzel, L. B., Joly, F., Eek, D., Rodrigues, M. J., Clamp, A. R., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.5507 · Cited by 18 · see citing works

Real-World Delivery of Rucaparib to Patients with Ovarian Cancer: Recommendations Based on an Integrated Safety Analysis of ARIEL2 and Study 10

Drew, Y., Kristeleit, R. S., Oaknin, A., Ray-Coquard, I. L., Haris, N. M., & Swisher, E. M. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-0229 · Cited by 17 · see citing works

PARP inhibitor rucaparib induces changes in NAD levels in cells and liver tissues as assessed by MRS

Almeida, G. S., Bawn, C. M., Galler, M., Wilson, I., Thomas, H. D., Kyle, S., Curtin, N. J., Newell, D. R., & Maxwell, R. J. (2017) · NMR in Biomedicine · doi:10.1002/nbm.3736 · Cited by 16 · see citing works

Pharmacokinetic Effects and Safety of Olaparib Administered with Endocrine Therapy: A Phase I Study in Patients with Advanced Solid Tumours

Plummer, R., Verheul, H. M. W., Vos, F. D., Leunen, K., Molife, L. R., Rolfo, C. D., Sørensen, P. G., Grève, J. D., Rottey, S., Jérusalem, G., et al. (2018) · Advances in Therapy · doi:10.1007/s12325-018-0804-z · Cited by 15 · see citing works

The role of dePARylation in DNA damage repair and cancer suppression

Kassab, M. A., & Yu, X. (2019) · DNA repair · doi:10.1016/j.dnarep.2019.02.002 · Cited by 14 · see citing works

Comparison of Poly (ADP-ribose) Polymerase Inhibitors (PARPis) as Maintenance Therapy for Platinum-Sensitive Ovarian Cancer: Systematic Review and Network Meta-Analysis

Stemmer, A., Shafran, I. H., Stemmer, S. M., & Tsoref, D. (2020) · Cancers · doi:10.3390/cancers12103026 · Cited by 14 · see citing works

Real world experience of poly (ADP-ribose) polymerase inhibitor use in a community oncology practice

Eakin, C. M., Ewongwo, A. N., Pendleton, L., Monk, B. J., & Chase, D. M. (2020) · Gynecologic Oncology · doi:10.1016/j.ygyno.2020.07.020 · Cited by 13 · see citing works

Management of nausea and vomiting from poly(ADP-ribose) polymerase inhibitor therapy for advanced ovarian cancer

Eakin, C. M., Norton, T. J., Monk, B. J., & Chase, D. M. (2020) · Gynecologic Oncology · doi:10.1016/j.ygyno.2020.08.016 · Cited by 12 · see citing works

A prospective evaluation of tolerability of niraparib dosing based upon baseline body weight (wt) and platelet (blplt) count: Blinded pooled interim safety data from the PRIMA Study

González, A. D., Mirza, M. R., Vergote, I. B., Li, Y., Hazard, S. J., Clark, R. S., Graybill, W. A. S., Pothuri, B., & Monk, B. J. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy285.150 · Cited by 12 · see citing works

Evaluation of clinical-stage PARP inhibitors in cell-based assays to correlate PARP suppression with functional impact on DNA repair

Wang, S., Woodgate, S., Potter, J., Lawo, S., & Mikule, K. W. (2016) · European Journal of Cancer · doi:10.1016/s0959-8049(16)32967-7 · Cited by 11 · see citing works

819P Efficacy and safety of niraparib in older patients (pts) with advanced ovarian cancer (OC): Results from the PRIMA/ENGOT-OV26/GOG-3012 trial

Valabrega, G., Pothuri, B., Oaknin, A., Graybill, W. A. S., Sánchez, A. B., Mccormick, C., Baurain, J. F., Hoskins, P. J., Denys, H. G., O'Cearbhaill, R. E., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.08.958 · Cited by 10 · see citing works

PARP inhibition as frontline therapy in ovarian cancer.

Moore, K. N., Pothuri, B., Monk, B. J., & Coleman, R. L. (2020) · PubMed · Cited by 8 · see citing works

Alternative mechanisms of inhibiting activity of poly ADP-ribose polymerase-1

Sriram, C. S. (2016) · Frontiers in Bioscience-Scholar · doi:10.2741/s452 · Cited by 7 · see citing works

In vitro metabolism of olaparib in liver microsomes by liquid chromatography/electrospray ionization high‐resolution mass spectrometry

Wang, L., & Wang, M. (2019) · Rapid Communications in Mass Spectrometry · doi:10.1002/rcm.8575 · Cited by 7 · see citing works

DNA Damage Response in Cancer Therapy and Resistance: Challenges and Opportunities

Jurkovičová, D., Neophytou, C. M., Gašparović, A. Č., & Gonçalves, A. C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232314672 · Cited by 170 · see citing works

Adverse Event Profiles of PARP Inhibitors: Analysis of Spontaneous Reports Submitted to FAERS

Tian, X., Chen, L., Gai, D., He, S., Jiang, X., & Zhang, N. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.851246 · Cited by 94 · see citing works

Three-dimensional modelling of ovarian cancer: from cell lines to organoids for discovery and personalized medicine

Yee, C., Dickson, K.-A., Muntasir, M. N., Ma, Y., & Marsh, D. J. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.836984 · Cited by 66 · see citing works

Managing Adverse Effects Associated With Poly (ADP-ribose) Polymerase Inhibitors in Ovarian Cancer: A Synthesis of Clinical Trial and Real-World Data

Friedlander, M. L., Lee, Y. C., & Tew, W. P. (2023) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_390876 · Cited by 50 · see citing works

Targeting key proteins involved in transcriptional regulation for cancer therapy: Current strategies and future prospective

Pei, H., Guo, W., Peng, Y., Xiong, H., & Chen, Y. (2022) · Medicinal Research Reviews · doi:10.1002/med.21886 · Cited by 45 · see citing works

Current Treatments and New Possible Complementary Therapies for Epithelial Ovarian Cancer

Garrido, M. P., Fredes, A. N., Lobos‐González, L., Valenzuela, M., Vera, D. B., & Romero, C. (2021) · Biomedicines · doi:10.3390/biomedicines10010077 · Cited by 40 · see citing works

Overexpression of ABCC1 and ABCG2 confers resistance to talazoparib, a poly (ADP-Ribose) polymerase inhibitor

Teng, Q., Lei, Z., Wang, J., Yang, Y., Wu, Z., Acharekar, N., Zhang, W., Yoganathan, S., Pan, Y., Wurpel, J. N. D., et al. (2023) · Drug Resistance Updates · doi:10.1016/j.drup.2023.101028 · Cited by 34 · see citing works

Pleiotropic role of PARP1: an overview

Kumar, V., Kumar, A., Mir, K. U. I., Yadav, V., & Chauhan, S. S. (2021) · 3 Biotech · doi:10.1007/s13205-021-03038-6 · Cited by 34 · see citing works

A genome-wide CRISPR-Cas9 knockout screen identifies novel PARP inhibitor resistance genes in prostate cancer

Ipsen, M. B., Sørensen, E. M. G., Thomsen, E. A., Weiss, S., Haldrup, J., Dalby, A., Palmfeldt, J., Bross, P., Rasmussen, M., Fredsøe, J., et al. (2022) · Oncogene · doi:10.1038/s41388-022-02427-2 · Cited by 34 · see citing works

PARP1: A comprehensive review of its mechanisms, therapeutic implications and emerging cancer treatments

Conceição, C. J. F., Moe, E., Ribeiro, P. A., & Raposo, M. (2025) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2025.189282 · Cited by 32 · see citing works

Two Cocrystals of Olaparib with Flavonoids toward Sustained Release: Structure, Dissolution Behavior, and Anticancer Activity Analysis

Duan, C., Chen, Y., Zhang, Y., Liang, F., Liu, W., Xiao, X., Xu, C., Zhuang, T., Hao, C., & Chen, Y. (2022) · Crystal Growth & Design · doi:10.1021/acs.cgd.2c00370 · Cited by 30 · see citing works

Precision Medicine in High-Grade Serous Ovarian Cancer: Targeted Therapies and the Challenge of Chemoresistance

Polajžer, S., & Černe, K. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26062545 · Cited by 27 · see citing works

AI-enhanced adaptive virtual screening of large libraries for ligand discovery

Cecchini, D., Nigam, A., Tang, M., Reis, J., Koop, M., Gottinger, A., Nicoll, C. R., Wang, Y., Jayaraj, A., Çınaroğlu, S. S., et al. (2026) · Nature Biotechnology · doi:10.1038/s41587-026-03217-x · Cited by 27 · see citing works

Advances in PARP Inhibitors for Prostate Cancer

Tisseverasinghe, S., Bahoric, B., Anidjar, M., Probst, S., & Niazi, T. M. (2023) · Cancers · doi:10.3390/cancers15061849 · Cited by 26 · see citing works

Evolving DNA repair synthetic lethality targets in cancer

Kulkarni, S., Brownlie, J., Jeyapalan, J. N., Mongan, N. P., Rakha, E. A., & Madhusudan, S. (2022) · Bioscience Reports · doi:10.1042/bsr20221713 · Cited by 25 · see citing works

Targeting Homologous Recombination Deficiency in Ovarian Cancer with PARP Inhibitors: Synthetic Lethal Strategies That Impact Overall Survival

Xie, T., Dickson, K.-A., Yee, C., Ma, Y., Ford, C. E., Bowden, N. A., & Marsh, D. J. (2022) · Cancers · doi:10.3390/cancers14194621 · Cited by 23 · see citing works

Systematic Analysis of the Therapy Resistance Genes and their Prognostic Relevance in Cervical Cancer

Eswaran, S., Padavu, M., Kumar, D., & Kabekkodu, S. P. (2023) · Current Pharmaceutical Design · doi:10.2174/1381612829666230816100623 · Cited by 21 · see citing works

Cancer stem cells markers in ovarian cancer: Clinical and therapeutic significance (Review)

Królewska‐Daszczyńska, P., Wendlocha, D., Smycz‐Kubańska, M., Stępień, S., & Mielczarek‐Palacz, A. (2022) · Oncology Letters · doi:10.3892/ol.2022.13585 · Cited by 21 · see citing works

Clinical Pharmacokinetics and Pharmacodynamics of Rucaparib

Liao, M., Beltman, J., Giordano, H., Harding, T. C., Maloney, L., Simmons, A. D., & Xiao, J. J. (2022) · Clinical Pharmacokinetics · doi:10.1007/s40262-022-01157-8 · Cited by 20 · see citing works

A synthetic lethal dependency on casein kinase 2 in response to replication-perturbing therapeutics in RB1-deficient cancer cells

Bulanova, D. R., Akimov, Y. A., Senkowski, W., Oikkonen, J., Gall-Mas, L., Timonen, S., Elmadani, M., Hynninen, J., Hautaniemi, S., Aittokallio, T. A., et al. (2024) · Science Advances · doi:10.1126/sciadv.adj1564 · Cited by 16 · see citing works

BUB1 Inhibition Sensitizes TNBC Cell Lines to Chemotherapy and Radiotherapy

Sriramulu, S., Thoidingjam, S., Siddiqui, F., Brown, S. L., Movsas, B., Walker, E., & Nyati, S. (2024) · Biomolecules · doi:10.3390/biom14060625 · Cited by 16 · see citing works

A radioiodinated rucaparib analogue as an Auger electron emitter for cancer therapy

Destro, G., Chen, Z., Chan, C. Y., Fraser, C., Dias, G., Mosley, M. J., Guibbal, F., Gouverneur, V., & Cornelissen, B. T. (2022) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2022.108312 · Cited by 16 · see citing works

The disruption of the CCDC6 – PP4 axis induces a BRCAness like phenotype and sensitivity to PARP inhibitors in high-grade serous ovarian carcinoma

Morra, F., Merolla, F., Damia, G. L. M., Ricci, F., Varricchio, S., Ilardi, G., Arenare, L., Califano, D., Napolitano, V., Fruscio, R., et al. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02459-2 · Cited by 15 · see citing works

Ovarian cancer in the older patient: where are we now? What to do next?

Rousseau, F., Ranchon, F., Bardin, C., Bakrin, N., Lavoué, V., Bengrine-Lefèvre, L., & Falandry, C. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359231192397 · Cited by 15 · see citing works

Poly (ADP-ribose) polymerase inhibitor therapy and mechanisms of resistance in epithelial ovarian cancer

Kulkarni, S., Gajjar, K. B., & Madhusudan, S. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1414112 · Cited by 15 · see citing works

The complex universe of inactive PARP1

Huang, D., Su, Z., Mei, Y., & Shao, Z. (2024) · Trends in Genetics · doi:10.1016/j.tig.2024.08.009 · Cited by 15 · see citing works

Pharmacological Strategies for Enzyme Inhibition in Disease Therapeutics: A Comprehensive Review

Verma, G., Bhushan, B., Singh, G., Singh, K., Kumar, S., Garg, A., & Rajput, P. (2023) · Current Enzyme Inhibition · doi:10.2174/0115734080273835231127045336 · Cited by 14 · see citing works

Characteristics of Extracellular Vesicles from a High-Grade Serous Ovarian Cancer Cell Line Derived from a Platinum-Resistant Patient as a Potential Tool for Aiding the Prediction of Responses to Chemotherapy

Černe, K., Kelhar, N., Resnik, N., Herzog, M., Vodnik, L., Veranič, P., & Kobal, B. (2023) · Pharmaceuticals · doi:10.3390/ph16060907 · Cited by 13 · see citing works

UBA1 inhibition sensitizes cancer cells to PARP inhibitors

Awasthi, S., Dobrolecki, L. E., Sallas, C., Zhang, X., Yang, L., Khazaei, S., Ghosh, S. K., Jeter, C. R., Liu, J., Mills, G. B., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101834 · Cited by 13 · see citing works

Role of PARP Inhibitors: A New Hope for Breast Cancer Therapy

De, K., Jana, M., Chowdhury, B., Calaf, G. M., & Roy, D. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26062773 · Cited by 12 · see citing works

Metabolism‑related pharmacokinetic drug‑drug interactions with poly (ADP‑ribose) polymerase inhibitors (Review)

Zhao, D., Long, X., & Wang, J. (2021) · Oncology Reports · doi:10.3892/or.2021.8231 · Cited by 12 · see citing works

The Synergistic Effect of Ruthenium Complex Δ-Ru1 and Doxorubicin in a Mouse Breast Cancer Model

Tang, X., Lin, K., Guo, S., Rong, Y., Chen, D., Chen, Z., Ping, F., & Wang, J. (2022) · Recent Patents on Anti-Cancer Drug Discovery · doi:10.2174/1574892817666220629105543 · Cited by 12 · see citing works

PARP Inhibitors Display Differential Efficacy in Models of BRCA Mutant High-Grade Serous Ovarian Cancer

Dickson, K.-A., Xie, T., Evenhuis, C., Ma, Y., & Marsh, D. J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168506 · Cited by 11 · see citing works

Safety assessments and clinical features of PARP inhibitors from real-world data of Japanese patients with ovarian cancer

Uekusa, R., Yokoi, A., Watanabe, E., Yoshida, K., Yoshihara, M., Tamauchi, S., Shimizu, Y., Ikeda, Y., Yoshikawa, N., Niimi, K., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-63600-z · Cited by 11 · see citing works

MassChemSite for In-Depth Forced Degradation Analysis of PARP Inhibitors Olaparib, Rucaparib, and Niraparib

Bonciarelli, S., Desantis, J., Cerquiglini, S., & Goracci, L. (2023) · ACS Omega · doi:10.1021/acsomega.2c07815 · Cited by 11 · see citing works

Multi-Disciplinary Care Planning of Ovarian Cancer in Older Patients: General Statement—A Position Paper from SOFOG-GINECO-FRANCOGYN-SFPO

Bengrine-Lefèvre, L., Bakrin, N., Rousseau, F., Lavoué, V., & Falandry, C. (2022) · Cancers · doi:10.3390/cancers14051295 · Cited by 11 · see citing works

Novel drug-drug co-amorphous systems of olaparib with nonsteroidal anti-inflammatory drugs with improved solubility, physical stability, antitumor activity and pharmacokinetics

Luo, Z.-K., Qin, H.-M., Han, J.-M., Zhu, J., Zeng, Y.-Y., Fan, C.-P., Liu, S., Hao, C., Zhang, J., & Zhuang, T. (2024) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2024.106232 · Cited by 10 · see citing works

Efficacy and safety of PARP inhibitors for maintenance treatment of ovarian cancer, regardless of BRCA or HRD status: a comprehensive updated meta-analysis

Li, Y. (2023) · Journal of Obstetrics and Gynaecology · doi:10.1080/01443615.2023.2171282 · Cited by 10 · see citing works

Identification of NAD+ Metabolism-Derived Gene Signatures in Ovarian Cancer Prognosis and Immunotherapy

Lin, L., Chen, L., Xie, Z., Chen, J., Li, L., & An, L. K. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.905238 · Cited by 10 · see citing works

Effectiveness and safety of PARP inhibitors in ovarian cancer: An umbrella review of systematic reviews and meta-analyses

Tzang, C.-C., Huang, E. S., Wu, H., Lin, W.-C., Lee, Y. T., Luo, C.-A., Chen, Y.-H., Chang, Z.-Y., Chen, Z.-T., Kuo, V. F.-H., et al. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104893 · Cited by 9 · see citing works

Potential agnostic role of BRCA alterations in patients with several solid tumors: One for all, all for one?

Fanale, D., Corsini, L. R., Pedone, E., Randazzo, U., Fiorino, A., Piazza, M. D., Brando, C., Magrin, L., Contino, S., Piraino, P., et al. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.104086 · Cited by 9 · see citing works

Safety and hematological toxicities of PARP inhibitors in patients with cancer: a systematic review of randomized controlled trials and a pharmacovigilance analysis

Dai, M., Wang, X., Xin, W., Kong, S., Xu, W., Ding, H., & Fang, L. (2024) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2024.2357822 · Cited by 9 · see citing works

Efficacy and safety of rucaparib in patients with recurrent high-grade ovarian carcinoma: A systematic review and meta-analysis

Adrianto, N., Mangkuliguna, G., Tandiono, E. J., & Sibarani, C. N. R. (2024) · Taiwanese Journal of Obstetrics and Gynecology · doi:10.1016/j.tjog.2024.05.020 · Cited by 9 · see citing works

Identification of immunity- and ferroptosis-related genes for predicting the prognosis of serous ovarian cancer

Yuan, X., Zhou, Q., Zhang, F., Zheng, W., Liu, H., Chen, A., & Tao, Y. (2022) · Gene · doi:10.1016/j.gene.2022.146701 · Cited by 8 · see citing works

Safety of PARP inhibitors as maintenance therapy in ovarian cancer

Cecere, S. C., Casartelli, C., Forte, M., Pignata, S., & Pisano, C. (2023) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2023.2254699 · Cited by 8 · see citing works

Comparison of poly (ADP-ribose) polymerase inhibitors (PARPis) as maintenance therapy for newly-diagnosed and platinum-sensitive recurrent ovarian cancer with BRCA mutational status: a systematic review and network meta-analysis

Zhou, S., Jiang, Y., Luo, C., & Yuan, L. (2024) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2023.2298832 · Cited by 8 · see citing works

Biomarkers of Central Nervous System Involvement from Epithelial Ovarian Cancer

Scotto, G., Borella, F., Turinetto, M., Tuninetti, V., Valsecchi, A. A., Giannone, G., Cosma, S. D., Benedetto, C., & Valabrega, G. (2021) · Cells · doi:10.3390/cells10123408 · Cited by 8 · see citing works

Factors for the development of anemia in patients with newly introduced olaparib: A retrospective case-control study

Shiraishi, C., Hirai, T., Kaneda, M. K., Okamoto, A., Kato, H., Tanaka, K., Kondo, E., Ikeda, T., & Iwamoto, T. (2023) · Medicine · doi:10.1097/md.0000000000034123 · Cited by 7 · see citing works

Inhibition of efflux transporters by poly ADP‐ribose polymerase inhibitors

Deng, F. Y., Sistonen, J., Neuvonen, M., & Niemi, M. (2023) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.13928 · Cited by 7 · see citing works

Olaparib enhancing radiosensitization and anti-metastatic effect of oral cancer by targeting IL-17A signal

Yu, C., Lin, H., Chan, M. W. Y., Wu, S., Chiou, W., Lee, M., Chi, C.-L., Lin, R., Hsu, F.-C., Yang, H.-J., et al. (2024) · Cancer Cell International · doi:10.1186/s12935-024-03547-3 · Cited by 7 · see citing works

Niraparib-induced STAT3 inhibition increases its antitumor effects

Zhao, Q., Kohut, A. Y., Li, Y., Martincuks, A., Austria, T., Zhang, C., Santiago, N. L., Borrero, R. M., Phan, X. T., Melstrom, L. G., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.966492 · Cited by 7 · see citing works

Role of Rucaparib in the Treatment of Prostate Cancer: Clinical Perspectives and Considerations

Wu, M. S., & Goldberg, H. (2022) · Cancer Management and Research · doi:10.2147/cmar.s353411 · Cited by 7 · see citing works

Co-Packaged PARP inhibitor and photosensitizer for targeted photo-chemotherapy of 3D ovarian cancer spheroids

Sorrin, A. J., Dasgupta, A., McNaughton, K. A., del Valle, C. A., Zhou, K., Liu, C., Roque, D. M., & Huang, H. (2024) · Cell & Bioscience · doi:10.1186/s13578-024-01197-6 · Cited by 7 · see citing works

Poly(ADP-ribose)polymerase 2 is zinc-dependent enzyme and nucleosome reorganizer

Maluchenko, N. V., Saulina, A., Geraskina, O. V., Kotova, E., Korovina, A. N., Armeev, G. A., Kirpichnikov, M. P., Feofanov, A. V., & Studitsky, V. M. (2025) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-025-05785-8 · Cited by 7 · see citing works

BRCA and Beyond: Impact on Therapeutic Choices Across Cancer

Tan, J. S. H., Zhang, Z., Goh, H. X., & Ngeow, J. Y. Y. (2024) · Cancers · doi:10.3390/cancers17010008 · Cited by 6 · see citing works

Unravelling the Role of PARP1 in Homeostasis and Tumorigenesis: Implications for Anti-Cancer Therapies and Overcoming Resistance

Lovsund, T., Mashayekhi, F., Fitieh, A. M., Stafford, J. L., & Ismail, I. H. (2023) · Cells · doi:10.3390/cells12141904 · Cited by 6 · see citing works

The effects of immune checkpoint inhibitors and targeted therapies on female fertility and ovarian function: a systematic review

Ateş, Ç., Dilbaz, B., Topçu, E. G., & Erkılınç, S. (2026) · International Journal of Gynecological Cancer · doi:10.1016/j.ijgc.2026.104697 · Cited by 5 · see citing works

Future of PARP inhibitors in cancer treatment: overcoming resistance and enhancing efficacy with combination therapies

Shoaib, M., Bhutta, Z. A., Javed, A., Amjad, M., Li, W., Choi, K., & Pu, W. (2025) · Journal of Zhejiang University SCIENCE B · doi:10.1631/jzus.b2400146 · Cited by 4 · see citing works

Comparative Assessment of Free Energy Computational Methods for Revealing the Interactions Driving PARP1 Selective Inhibition

Feito, A., DeMoya‐Valenzuela, N., Privat, C., Tejedor, A. R., DelValle-Carrillo, M., Cembellín, S., Paniagua‐Herranz, L., Garaizar, A., Oller-Iscar, J., Ocana, A., et al. (2026) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.6c00083 · Cited by 4 · see citing works

Drug-Induced Interstitial Lung Disease From PARP Inhibitors (Olaparib and Niraparib) for Ovarian Cancer

Sugimoto, H., Enomoto, T., Okuno, M., Chayahara, N., Morita, H., & Nakata, K. (2023) · Annals of Internal Medicine Clinical Cases · doi:10.7326/aimcc.2022.0711 · Cited by 4 · see citing works

Poly(Adenosine Diphosphate Ribose) Polymerase (PARP) Inhibitors in the Treatment of Advanced Ovarian Cancer: A Narrative Review

Dewani, D., Jaiswal, A., & Karwade, P. (2024) · Cureus · doi:10.7759/cureus.68463 · Cited by 4 · see citing works

Recent advancements in therapeutic biomarkers, associated challenges and considerations to overcome these challenges in prostate cancer (Review)

Gandupalli, L., Bhowmik, D., Jyotishi, C., & Gupta, R. (2025) · World Academy of Sciences Journal · doi:10.3892/wasj.2025.313 · Cited by 4 · see citing works

Safety and efficacy of Rucaparib in the treatment of ovarian cancer and patients with BRCA mutation: a systematic review and meta-analysis of phase III randomized clinical trials

Mustafa, M. T., Abushanab, A. K., Mousa, M. T., Qawaqzeh, R. A., Alakhras, H. M., Othman, A. S., & Saed, A. (2024) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2024.2309177 · Cited by 4 · see citing works

Influence of differential source patterns in the detection of signals of disproportionate reporting for PARP inhibitors

Mestres, J. (2024) · Frontiers in Drug Safety and Regulation · doi:10.3389/fdsfr.2024.1497116 · Cited by 3 · see citing works

A comprehensive comparison of PARP inhibitors as maintenance therapy in platinum-sensitive recurrent ovarian cancer: a systematic review and network meta-analysis

Ji, S., Chen, L., Yu, Y. L., Chen, X., Wei, L., Gou, L., Shi, C., & Zhuang, S. (2025) · Journal of Ovarian Research · doi:10.1186/s13048-025-01599-1 · Cited by 3 · see citing works

Gentian Violet Inhibits Cell Proliferation through Induction of Apoptosis in Ovarian Cancer Cells

Choi, M. S., Kim, J. H., Lee, C. Y., Lee, Y. M., Lee, S., Chang, H. K., Kim, H. J., & Heo, K. (2023) · Biomedicines · doi:10.3390/biomedicines11061657 · Cited by 3 · see citing works

A Novel Notch-Related Gene Signature for Prognosis and Immune Response Prediction in Ovarian Cancer

Pi, Y., Sun, F., Zhang, Z., Liu, X., & Lou, G. (2023) · Medicina · doi:10.3390/medicina59071277 · Cited by 3 · see citing works

BRCA1/2 NGS Somatic Testing in Clinical Practice: A Short Report

Pepe, F., Pisapia, P., Russo, G., Nacchio, M., Pallante, P., Vigliar, E., Angelis, C. D., Insabato, L., Bellevicine, C., Placido, S. D., et al. (2021) · Genes · doi:10.3390/genes12121917 · Cited by 3 · see citing works

Attenuation of Muscle Damage, Structural Abnormalities, and Physical Activity in Respiratory and Limb Muscles following Treatment with Rucaparib in Lung Cancer Cachexia Mice

Pérez-Peiró, M., Durán, X., Yélamos, J., & Barreiro, E. (2022) · Cancers · doi:10.3390/cancers14122894 · Cited by 3 · see citing works

Tolerance of Olaparib in a Patient With Unresectable Serous Gynecologic Cancer and End-Stage Renal Disease

Goon, K. C., & Alldredge, J. K. (2023) · Cureus · doi:10.7759/cureus.36505 · Cited by 2 · see citing works

Predictive value of homologous recombination deficiency status for survival outcomes in primary tubo-ovarian high-grade serous carcinoma

Zwimpfer, T. A., Ewald, H., Bilir, E., Jayawardana, M., Appenzeller‐Herzog, C., Bizzarri, N., Razumova, Z., Kacperczyk-Bartnik, J. P., Heinzelmann-Schwarz, V. A., Friedlander, M. L., et al. (2024) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd015896 · Cited by 2 · see citing works

Effectiveness and safety of PARP inhibitors in breast cancer: An umbrella review of systematic reviews and meta-analyses

Tzang, C.-C., Wu, H.-W., Luo, C.-A., Huang, E. S., Lin, W., Chen, Y.-H., Chang, Z.-Y., Lee, Y.-T., Kang, Y.-F., Tzang, B.-S., et al. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.105048 · Cited by 2 · see citing works

Evaluating carboplatin and PARP inhibitor combination efficacy using high-grade serous carcinoma spheroids and organoids

Tomas, E. J., Davis, J., Valdés, Y. R., & Shepherd, T. G. (2026) · Cancer Biology & Therapy · doi:10.1080/15384047.2025.2611602 · Cited by 2 · see citing works

Survival analysis of recurrent ovarian cancer under different PARP inhibitor treatment patterns: a single-center retrospective study

Shen, J., Wang, X., Olivier, M., Wang, Y., Shan, Y., Lou, X., Ye, P., & Yan, X. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2024.1504084 · Cited by 2 · see citing works

Overview of Roles of Novel Components in the Regulation of DNA Damage Repair in BRCA1-Deficient Cancers: An Update

Nguyen, N., Arris, D., & Tran, M. T. (2025) · DNA · doi:10.3390/dna5020017 · Cited by 1 · see citing works

Quality-adjusted progression-free survival analysis of veliparib and carboplatin/paclitaxel compared with chemotherapy alone in patients with newly diagnosed ovarian cancer (VELIA/GOG3005): ancillary analysis of a placebo-controlled, phase 3 randomized trial

Lafferty, J., Secord, A. A., Bookman, M. A., Coleman, R. L., Dinh, M. H., Khandelwal, N., Kamalakar, R., & Cella, D. F. (2025) · International Journal of Gynecological Cancer · doi:10.1016/j.ijgc.2025.102819 · Cited by 1 · see citing works

From dual inhibition to precision selectivity: the molecular rationale and clinical evolution of next-generation PARP1-selective inhibitors in solid tumors

Ayoub, M. M., Osman, S. A., Alkarbi, R. M., Anjum, R., & Malki, A. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1894818 · Cited by 1 · see citing works

Genitourinary Cancer: Updates on Treatments and Their Impact on the Kidney

Scott, P. O., Deshpande, P., & Abramson, M. H. (2022) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2023.151344 · Cited by 1 · see citing works

A PARP inhibitor, rucaparib, improves cardiac dysfunction in ADP-ribose-acceptor hydrolase 3 ( Arh3 ) deficiencyPreprint

Yamashita, S., Bu, X., Ishiwata-Endo, H., Kato, J., Springer, D., Noguchi, A. C., Peiravi, M., Liu, C., Zhang, F., Yu, Z., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.02.07.527369 · Cited by 1 · see citing works

The evolving landscape of PARP inhibitors in castration-resistant prostate cancer: a spotlight on treatment combinations

Teply, B. A., & Antonarakis, E. S. (2022) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2022.2140656

Genomic instability as a predictive biomarker for the application of DNA-damaging therapies in gynecological cancer patients

Reig, R. L. (2023) · doi:10.4995/thesis/10251/199026

Health care services utilization in patients with ovarian cancer receiving PARP inhibitor maintenance treatment in a US community oncology setting

Chase, D. M., Annavarapu, S., Tseng, W.-Y., Shi, J., Szamreta, E. A., & Monberg, M. (2023) · Gynecologic Oncology · doi:10.1016/j.ygyno.2023.11.016

Discovery of Potent Isoindolinone Inhibitors that Target an Active Conformation of PARP1 Using DNA‐Encoded Libraries

McCarthy, K. A., Marcotte, D. J., Parelkar, S. S., McKinnon, C. L., Trammell, L. E., Stangeland, E. L., & Jetson, R. R. (2024) · ChemMedChem · doi:10.1002/cmdc.202400093

Prognosis and Therapy of Ovarian Cancer: Part 2 – the Shifting Landscape of Medical Treatment in Ovarian Cancer

Varela, S. T., Housheimi, A. E., & Kuhn, W. C. (2025) · Oncology Research and Treatment · doi:10.1159/000546245

Additional file 4 of The disruption of the CCDC6 – PP4 axis induces a BRCAness like phenotype and sensitivity to PARP inhibitors in high-grade serous ovarian carcinoma

Morra, F., Merolla, F., Damia, G. L. M., Ricci, F., Varricchio, S., Ilardi, G., Arenare, L., Califano, D., Napolitano, V., Fruscio, R., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20486665

Additional file 1 of Co-Packaged PARP inhibitor and photosensitizer for targeted photo-chemotherapy of 3D ovarian cancer spheroids

Sorrin, A. J., Dasgupta, A., McNaughton, K. L., Arnau Del Valle, C., Zhou, K., Liu, C., Roque, D. M., & Huang, H. C. (2024) · Figshare · doi:10.6084/m9.figshare.26677628

Additional file 3 of The disruption of the CCDC6 – PP4 axis induces a BRCAness like phenotype and sensitivity to PARP inhibitors in high-grade serous ovarian carcinoma

Morra, F., Merolla, F., Damia, G. L. M., Ricci, F., Varricchio, S., Ilardi, G., Arenare, L., Califano, D., Napolitano, V., Fruscio, R., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20486662

Additional file 1 of The disruption of the CCDC6 – PP4 axis induces a BRCAness like phenotype and sensitivity to PARP inhibitors in high-grade serous ovarian carcinoma

Morra, F., Merolla, F., Damia, G. L. M., Ricci, F., Varricchio, S., Ilardi, G., Arenare, L., Califano, D., Napolitano, V., Fruscio, R., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20486656

Niraparib PBPK modeling to predict optimal dosage in patients with hepatic impairment

Pokladyuk, A., Voronova, V., Helmlinger, G., Peskov, K. V., & Kosinsky, Y. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1736762

Ovarian cancer: Tumor microenvironment

Soni, A., Gohil, T., Kaba, Z., Panchal, K., Mafat, A., Ghelani, D., Mehta, H., Khasatiya, P., & Mandaliya, V. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-36783-0.00017-4

Olaparib: Analytical methods for the quantification in drug substance, pharmaceutical formulations and biological matrices

Rangrej, S. H., Chadar, D., Gour, S., Sahu, S., Patil, U. K., Kshirsagar, R. V., & Pawde, D. M. (2026) · Journal of Liquid Chromatography & Related Technologies · doi:10.1080/10826076.2026.2705482

A retrospective analysis of adverse drug reaction case reports for PARP inhibitors: a comparative study of olaparib and niraparib

Zou, D., Yao, J., & Zang, Z. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1935594

Mechanism and current progress of Poly ADP-ribose polymerase (PARP) inhibitors in the treatment of ovarian cancer

Zheng, F., Zhang, Y., Chen, S., Weng, X., Rao, Y., & Hongmei, F. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109661 · Cited by 138 · see citing works

Update on poly(ADP-ribose) polymerase inhibitors resistance in ovarian cancer

Dong, R., Ding, T., & Li, Z. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1164395 · Cited by 10 · see citing works

PARP inhibitors: risk factors for toxicity and matching patients to the proper poly (ADP-ribose) polymerase inhibitor (PARPi) therapy

Chelariu-Raicu, A., Trillsch, F., Burges, A., Czogalla, B., Hester, A., Wuerstlein, R., Harbeck, N., & Mahner, S. (2023) · International Journal of Gynecological Cancer · doi:10.1136/ijgc-2022-003990 · Cited by 12 · see citing works

Poly-ADP-ribose polymerase (PARP) inhibitors and ovarian function

Li, J., Li, Q., Zhang, L., Zhang, S., & Dai, Y. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.114028 · Cited by 23 · see citing works

PARP Inhibitors in Ovarian Cancer: Resistance Mechanisms, Clinical Evidence, and Evolving Strategies

Apelian, S., Martincuks, A., Whittum, M., Yasukawa, M., Nguy, L. K., Mathyk, B. A., Andikyan, V., Anderson, M. L., Rutherford, T., Cristea, M. C., et al. (2025) · Biomedicines · doi:10.3390/biomedicines13051126 · Cited by 20 · see citing works